26.09.2012 - The Berlin-based epigenetics specialist Epigenomics AG has changed its CEO with immediate effect.
Thomas Taapken, formerly CFO will replace his boss Geert Nygaard who will leave the company on September 30. “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. One year ago, the Berlin-based diagnostics specialist halved its workforce to about 40 staff in the light of a corporate restructuring. Among other things, Epigenomics stopped its own marketing for the Epiprocolon blood test to detect colon cancer in Germany. The focus of the company was turned to the US market where the company runs a clinical study as the basis for a possible FDA approval. The underlying Septin9 marker was out-licensed non-exclusively to a number of partners. However, revenues from this operation do not compensate for the company's development spending. At the end of the second quarter, Epigenomics had €9.1m in cash with a loss of about €5.7m in the first half of 2012.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more